Lupin is currently trading at Rs. 920.20, up by 21.50 points or 2.39% from its previous closing of Rs. 898.70 on the BSE.
The scrip opened at Rs. 909.65 and has touched a high and low of Rs. 923.10 and Rs. 905.05 respectively. So far 236595 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1194.00 on 15-Jun-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.
Last one week high and low of the scrip stood at Rs 923.10 and Rs. 805.25 respectively. The current market cap of the company is Rs. 41663.13 crore.
The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.
Lupin has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s (Bayer) Beyaz Tablets.
Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of around $82.2 million in the US (IQVIA MAT April 2018).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
